Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) had its price objective reduced by HC Wainwright from $60.00 to $40.00 in ...

Jane Street Group LLC bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) during the third quarter, ...

Analyst Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report) and keeping the price ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR), with a market capitalization of $105.23 million, is a clinical-stage biotechnology company focused on developing innovative treatments for mast cell ...

RBC Capital analyst Gregory Renza lowered the firm’s price target on Jasper Therapeutics (JSPR) to $48 from $68 and keeps an Outperform rating ...

Jasper Therapeutics Inc (JSPR) stock saw a decline, ending the day at $6.99 which represents a decrease of $-10.72 or -60.53% from the prior close of $17.71. The stock opened at $8.74 and touched a ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR), with a market capitalization of $105.23 million, is a clinical-stage biotechnology company focused on developing innovative treatments for mast cell-mediated ...

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...

Explore why the iShares Russell 2000 ETF IWM has crashed hard this year amid the ongoing bond yield surge in the US.